<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127780">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01941875</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00032793</org_study_id>
    <nct_id>NCT01941875</nct_id>
  </id_info>
  <brief_title>Luteal Phase Progesterone in IUI and Gonadotropin Cycles</brief_title>
  <official_title>The Effect of Luteal Phase Support on Pregnancy Rate in Intrauterine Insemination Cycles Following Ovarian Stimulation With Gonadotropins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of patients undergoing Controlled Ovarian Hyperstimulation (COH) with
      Gonadotropins and Intrauterine Insemination (IUI) at a Fertility Clinic.

      Infertility is a common problem, and a popular method of therapy is to inject sperm through
      the cervix and into the uterus, a procedure known as IUI.  In conjunction with IUI,
      injectable medications (gonadotropins) are used to stimulate the ovaries to produce more
      than one egg per cycle in a process called COH.

      Vaginal progesterone is used for luteal support in in vitro fertilization therapy and has
      been proven to effect pregnancy rates.  However, the role of progesterone in COH is still
      unclear.  In this study, the investigators want to examine the effect of giving vaginal
      progesterone after COH with IUI on pregnancy rates.   The investigators want to study if
      luteal vaginal progesterone results in a higher pregnancy rate compared to no progesterone
      therapy in COH with IUI.  At present, fertility centres vary in the use of progesterone
      after insemination, most likely due to the lack of studies on this subject.

      At the Fertility Clinic all patients undergoing COH with injectable medications and IUI,
      regardless of whether they are in the study, have a baseline transvaginal ultrasound and
      blood tests. Patients start the injectable medications for COH until the ovarian follicles
      are large enough, then a medication to release the eggs is given.  The IUI is done
      approximately 36 hours later.  The day after the IUI, study patients will be given vaginal
      progesterone while the control patients will receive no progesterone.  All patients will be
      followed until a pregnancy test is done and a viable foetus is confirmed by ultrasound.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>After 6 weeks gestational age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Presence of a fetal heart beat after 6 weeks gestational age</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical Pregnancy</measure>
    <time_frame>After 6 weeks gestational age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biochemical pregnancy rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-viable Pregnancy</measure>
    <time_frame>After 6 weeks gestational age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non-viable pregnancy rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Pregnancy</measure>
    <time_frame>After 6 weeks gestational age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Multiple pregnancy rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>No Luteal Support</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group: No luteal phase support or medication will be used</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Luteal Vaginal Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experiment group:  Vaginal progesterone for luteal support beginning the first day after IUI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone Effervescent Vaginal Tablets</intervention_name>
    <description>Experimental</description>
    <arm_group_label>Luteal Vaginal Progesterone</arm_group_label>
    <other_name>Endometrin 100 mg twice daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Couples with infertility

          -  Confirmed bilateral tubal patency

          -  More than 10 million motile sperm available for IUI

        Exclusion Criteria:

          -  Subjects declining enrollment

          -  Allergies to prescribed vaginal progesterone

          -  Subjects less than 21 years old or over 43 years old
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tarek Motan, MB ChB</last_name>
    <phone>780-735-5604</phone>
    <email>tmotan@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jinglan Han, MD</last_name>
    <phone>780-735-5604</phone>
    <email>jinglan@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fertility &amp; Womens Endocrine Clinic, Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tarek Motan, MB ChB</last_name>
      <phone>780-735-5604</phone>
      <email>tmotan@ualberta.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jinglan Han, MD</last_name>
      <phone>780-735-5604</phone>
      <email>jinglan@ualberta.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Tarek Motan, MB ChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinglan Han, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>September 9, 2013</lastchanged_date>
  <firstreceived_date>August 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>controlled ovarian hyperstimulation</keyword>
  <keyword>gonadotropins</keyword>
  <keyword>intrauterine insemination</keyword>
  <keyword>infertility</keyword>
  <keyword>luteal progesterone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
